Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 10/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369808 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTHRH1HRH3HRH2 | |
| SCHEMBL7816746 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTHRH1HRH3HRH2 | |
| SCHEMBL6583404 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTHRH1HRH3HRH2 | |
| SCHEMBL9658514 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTHRH1HRH3HRH2 | |
| Hydrochloric Acid SCHEMBL6584989 | 0.98 | TBXAS1 (0.60) | TBXAS1TERTHRH1HRH3HRH2 | |
| SCHEMBL1028789 | 0.98 | TBXAS1 (0.56) | TBXAS1TERTHRH1HRH3HRH2 | |
| Hydrochloric Acid SCHEMBL9659463 | 0.96 | TBXAS1 (0.57) | TBXAS1TERTHRH1HRH3HRH2 | |
| SCHEMBL72312 | 0.92 | — | — | |
| Bromide SCHEMBL29037591 | 0.90 | TBXAS1 (0.51) | TBXAS1TERTHRH3HRH4ALOX15 | |
| Hydrochloric Acid SCHEMBL11095387 | 0.90 | TBXAS1 (0.54) | TBXAS1TERTHRH3HRH4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| US-7109329-B2 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC | 2006-09-19 | — | — | US | disclosed |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC (US) | 2004-05-13 | — | — | US | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| EP-1157008-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050405-A1 | QUINOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-31 | — | — | WO | disclosed |
| US-5958933-A | HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS | NAFTCHI N ERIC (US) | 1999-09-28 | — | — | US | disclosed |
| US-5081131-A | Omega-((hetero)alkyl)benz(cd)-indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TBXAS1 1341/4885TERT 4233/4885HRH1 217/4885 |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | ACHE, GRIN2A, GRIK2 | TBXAS1 1347/4885TERT 4124/4885HRH1 4163/4885 |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | TBXAS1 544/4885TERT 4807/4885HRH1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.